Yu ZHU, Kunlun TIAN, Yue WU, et al. Beneficial effects of a new hemoglobin substitute on functions of vital organs in traumatic hemorrhagic shock rats[J]. Journal of Third Military Medical University, 2018, 40(19): 1729-1734.
DOI:
Yu ZHU, Kunlun TIAN, Yue WU, et al. Beneficial effects of a new hemoglobin substitute on functions of vital organs in traumatic hemorrhagic shock rats[J]. Journal of Third Military Medical University, 2018, 40(19): 1729-1734. DOI: 10.16016/j.1000-5404.201803174.
Beneficial effects of a new hemoglobin substitute on functions of vital organs in traumatic hemorrhagic shock rats
To investigate the effects of a new type hemoglobin substitute (product code YQ) on main organ functions in uncontrolled hemorrhagic shock rats.
Methods
2
A total of 100 SD rats (50 males and 50 females
at an age of 12 weeks
body weight 220±20 g) were randomly divided into 5 groups: 0.5%YQ
2.0%YQ
5%YQ
lactate Ringer's solution (LR) group
and whole blood group
with 20 rats in each group. After the uncontrolled hemorrhagic shock model was established in the rats by cutting off the splenic artery branch
the effects of different concentrations of YQ on vital organ blood flow (liver and kidneys)
functions of the liver and kidneys
and transcutaneous partial pressures of oxygen and blood gases were tested at vary resuscitation stages (resuscitation being maintained at 50
70 and 80 mmHg
in 1 and 2 h after resuscitation).
Results
2
① Compared with LR
all 3 doses of YQ increased PaO
2
and SaO
2
at different resuscitation stages; At 2 h post-resuscitation stage
the 2% YQ (98.8±15.9 mmHg) and 5% YQ groups (98.6±14.1 mmHg) showed better effects on PaO
2
than the LR group (68.6±5.6 mmHg
P
<
0.01)
while so were their effects on SaO
2
(92.1±2.5 and 93.6±2.4
vs
70.6±8.5 mmHg
P
<
0.01)
which was similar to that of the whole blood group (94.3±3.3 mmHg). ② All the 3 doses of YQ enhanced the transcutaneous oxygen pressures at different resuscitation stages
and 5% YQ presented the best effect
with its effect closed to that of the whole blood group at 2 h post-resuscitation stage (80.4±5.9
vs
80.0±7.3 mmHg)
while significantly higher than that of the LR group (59.1±1.6 mmHg
P
<
0.01). ③ The liver and kidney blood flows were elevated in all the 3 YQ groups at different resuscitation stages. Among them
the 5% YQ had the best effect
with the effects equivalent to those of the whole blood group at 2 h post-resuscitation stage (liver: 218.7±13.8
vs
220.4±18.2 U/min; kidneys: 187.4±10.9
vs
179.2±16.3 U/min) and better than those of the LR group (liver: 171.4±20.4 U/min; kidneys: 169.4±4.7 U/min). ④ The levels of AST
ALT
BUN and Crea were all reduced in the 3 YQ groups at different resuscitation stages. The 5% YQ group had significantly decreased AST (209.6±15.6
vs
149.8±13.7 U/L)
ALT (54.9±3.6
vs
45.9±4.2 U/L)
BUN (10.8±2.5
vs
9.7±1.8 mmol/L) and Crea (47.7±4.4
vs
25.8±2.1 μmol/L) when compared with the LR group at 2 h post-resuscitation stage.
Conclusion
2
YQ exerts protective effect on uncontrolled hemorrhagic shock via improving liver and kidney functions.
关键词
Keywords
references
LOZANO R, NAGHAVI M, FOREMAN K, et al . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J ] . Lancet, 2012, 380(9859): 2095- 2128. DOI:10.1016/S0140-6736(12)61728-0.
WU D, ZHOU X, YE L, et al . Emergency department crowding and the performance of damage control resuscitation in major trauma patients with hemorrhagic shock[J ] . Acad Emerg Med, 2015, 22(8):915-921. DOI:10.1111/acem.12726.
TRAN A, YATES J, LAU A, et al . Permissive Hypotension vs. conventional resuscitation strategies in adult trauma patients with hemorrhagic shock: a systematic review and meta-analysis of randomized controlled trials[J ] . J Trauma Acute Care Surg, 2018, 84(5):802-808. DOI:10.1097/TA.0000000000001816.
MASOUMI K, FOROUZAN A, DARIAN A A, et al . Comparison of the effectiveness of hydroxyethyl starch (voluven) solution with normal saline in hemorrhagic shock treatment in trauma[J ] . J Clin Med Res, 2016, 8(11):815-818. DOI:10.14740/jocmr2702w.
HOWARTH C, BANERJEE J, ALADANGADY N. Red blood cell transfusion in preterm infants: current evidence and controversies[J]. Neonatology, 2018, 114(1):7-16. DOI: 10.1159/000486584.
TAGUCHI K, YAMASAKI K, MARUYAMA T, et al . Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers[J ] . J Funct Biomater, 2017, 8(1): 11-18. DOI: 10.3390/jfb8010011.
KEIPERT P E. Hemoglobin-based oxygen carrier (HBOC) development in trauma: previous regulatory challenges, lessons learned, and a path forward.[J]. Adv Exp Med Biol, 2017, 977: 343-350. DOI: 10.1007/978-3-319-55231-6_45.
SHEN Y, ZHU W, ZHAO M, et al . Study of the pharmacokinetics of polymerized porcine hemoglobin (pPolyHb)[J ] . Artif Cells Nanomed Biotechnol, 2018, 11: 1-7. DOI: 10.1080/21691401.2018.1446020.
RATANASOPA K, CEDERVALL T, BVLOW L. Possibilities of using fetal hemoglobin as a platform for producing hemoglobin-based oxygen carriers (HBOCs)[J]. Adv Exp Med Biol, 2016, 876: 445-453.DOI: 10.1007/978-1-4939-3023-4_56.
PACO L, DR A G, DRONE J, et al . Catalase-lik e activity of bovine met-hemoglobin: Interaction with the pseudo-catalytic peroxidation of anthracene traces in aqueous medium[J ] . Biotech J, 2010, 4(10): 1460-1470. DOI: 10.1002/biot.200900100.
MOZZARELLI A, RONDA L, FAGGIANO S, et al . Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions[J ] . Blood Transfusion, 2010, 3(4): s59-68.DOI: 10.2450/2010.010S.
KUDO D, YOSHIDA Y, KUSHIMOTO S. Permissive hypotension/hypotensive resuscitation and restricted/controlled resuscitation in patients with severe trauma[J]. J Intens Care, 2017, 5(1): 11-18. DOI10.1186/s40560-016-0202-z.
LI T, ZHU Y, HU Y, et al . Ideal permissive hypotension to resuscitate uncontrolled hemorrhagic shock and the tolerance time in rats[J ] . Anesthesiology, 2011, 114(1): 111-119. DOI: 10.1097/ALN.0b013e3181fe3fe7.
POSLUSZNY J A, NAPOLITANO L M. Hemoglobin-based oxygen carrier for traumatic hemorrhagic shock treatment in a Jehovah's witness[J]. Arch Trauma Res, 2016, 5(2): e30610.DOI: 10.5812/atr.30610.